Clinical trial
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
NCT00293319 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00293319 |
|---|---|
| Title | 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma |
| Official title | I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological, Radiation |
| Interventions | filgrastim, iobenguane I 131 |
| Enrollment | 164 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Feb 17, 2006 |
| Last update posted | Aug 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: